| abstract |
The present invention provides antibodies characterized by binding to the p19 subunit of human IL-23 and having selective neutralizing properties of high affinity. The antibody is useful for the treatment or prevention of autoimmune or inflammatory conditions selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, graft versus host disease, lupus and metabolic syndrome. Antibodies are also useful in the treatment of cancer. |